跳至主要内容
临床试验/NCT01860508
NCT01860508Unknown不适用

Advanced Metastatic Non-small Cell Lung Cancer Patients Aged or PS Score 2 Points for First Line Application Pemetrexed/Carboplatin Chemotherapy Regimens Sequential Pemetrexed Single Drug Maintenance Treatment of Clinical Research and Related Predictive Biomarkers of Exploratory Research

Fudan University1 个研究点 分布在 1 个国家目标入组 94 人开始时间: 2013年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
94
试验地点
1
主要终点
PFS

研究概览

简要总结

PFS

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
70 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • .≥65 years or PS 2
  • Patients who were diagnosed by the histologic, cytologic diagnosis of IV non-small cell lung cancer
  • Patients received no chemical therapy or only received targeted therapy,and there is evidence show the patent is PD
  • Presence of at least one index lesion measurable by CT scan or MRI
  • leucocyte ≥ 3.5×109/L
  • neutrophil ≥ 1.5×109/L
  • platelet ≥ 80×109/L
  • Hemoglobin ≥ 9g/L
  • ALT and AST ≤ 2.5×ULN ,Tbil≤ 1.5×ULN
  • BUN≤ 1.5×ULN
  • Signed written informed consent

排除标准

  • squamous carcinoma or small cell lung cancer
  • Patients were allergic to pemetrexed
  • Patients received chemotherapy before
  • Uncontrolled acute infection
  • .Uncontrolled pleural effusion
  • Severe symptomatic heart disease
  • Severe infection or metabolic disfunction
  • Patients with other malignant tumor
  • Uncontrolled brain metastases
  • Patients have accepted other clinical trials
  • Female patients during their pregnant and lactation period, or patients without contraception
  • Mental disorientation of disorder
  • Glucocorticoids taboo

研究组 & 干预措施

pemetrexed

Experimental

干预措施: pemetrexed /carboplatin (Drug)

结局指标

主要结局

PFS

时间窗: from the first cycle of treatment (day one) to two month after the last cycle

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jialei Wang

Attending doctor of medical oncology

Fudan University

研究点 (1)

Loading locations...

相似试验